http://www.pharmabiz.com/NewsDetails.aspx?aid=157499&sid=2 WebIn the ongoing global, randomized, double-blind phase 3 KEYNOTE-811 study, we are assessing whether adding pembrolizumab to trastuzumab and chemotherapy improves …
Efficacy of Pembrolizumab Monotherapy in Japanese Patients
WebDesign, Setting, and Participants The phase 3 KEYNOTE-062 randomized, controlled, partially blinded interventional trial enrolled 763 patients with untreated, locally advanced/unresectable or metastatic G/GEJ cancer with PD-L1 CPS of 1 or greater from 200 centers in 29 countries between September 18, 2015, and May 26, 2024. Web22 mrt. 2024 · Efficacy was evaluated in KEYNOTE-590 (NCT03189719), a multicenter, randomized, placebo-controlled trial that enrolled 749 patients with metastatic or locally … teacher education at secondary level
KEYNOTE-062: Pembrolizumab Combination Fails to Improve …
WebThe KEYNOTE-059 study is a multicenter, open-label, nonrandomized, 3-cohort, phase 2 trial of pembrolizumab that was conducted at 67 sites in 17 countries in patients with … Web22 jan. 2024 · TPS263 Background: For patients with unresectable, locally advanced recurrent or metastatic G/GEJ cancer, the standard of care includes a fluoropyrimidine … Web10 apr. 2024 · In the single-arm, multicohort, phase 2 KEYNOTE-059 study, patients with advanced gastric/GEJ cancer in cohort 1 received pembrolizumab in the third-line or later setting . Among 148 patients with PD-L1-positive tumors, durable antitumor activity was observed (objective response rate (ORR), 15.5%; median duration of response (DOR), … teacher education building